Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the stock.

Several other equities research analysts have also issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC dropped their price target on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Raymond James began coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday. Finally, Piper Sandler decreased their target price on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $16.11.

Inozyme Pharma Stock Performance

Inozyme Pharma stock opened at $1.06 on Tuesday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 1 year low of $0.98 and a 1 year high of $7.80. The company’s 50-day moving average is $1.55 and its two-hundred day moving average is $3.30. The company has a market cap of $68.09 million, a PE ratio of -0.68 and a beta of 1.32.

Institutional Investors Weigh In On Inozyme Pharma

Hedge funds have recently made changes to their positions in the business. Harvest Investment Services LLC bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at $31,000. Graham Capital Management L.P. purchased a new stake in shares of Inozyme Pharma in the fourth quarter worth about $33,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $38,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Inozyme Pharma during the fourth quarter worth approximately $49,000. Finally, ProShare Advisors LLC purchased a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.